The Current Ratio as of October 2024 (TTM) for Prometheus Biosciences, Inc. (RXDX) is 37.56

According to Prometheus Biosciences, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 37.56. This represents a change of 61.36% compared to the average of 23.28 of the last 4 quarters.

Prometheus Biosciences, Inc. (RXDX) Historical Current Ratio (quarterly & annually)

How has RXDX Current Ratio performed in the past?

The mean historical Current Ratio of Prometheus Biosciences, Inc. over the last ten years is 10.51. The current 37.56 Current Ratio has changed 35.65% with respect to the historical average. Over the past ten years (40 quarters), RXDX's Current Ratio was at its highest in in the March 2023 quarter at 37.56. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Prometheus Biosciences, Inc. (RXDX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Prometheus Biosciences, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Prometheus Biosciences, Inc. (RXDX) Average Current Ratio

How has RXDX Current Ratio performed in the past?

The current Current Ratio of Prometheus Biosciences, Inc. (RXDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Prometheus Biosciences, Inc. (RXDX) Current Ratio vs. Peers

How is RXDX’s Current Ratio compared to its peers?

Prometheus Biosciences, Inc.’s Current Ratio is greater than Apellis Pharmaceuticals, Inc. (5.08), greater than Akero Therapeutics, Inc. (24.89), greater than Immunovant, Inc. (13.08), greater than Madrigal Pharmaceuticals, Inc. (8.72), greater than Roivant Sciences Ltd. (27.91), greater than Krystal Biotech, Inc. (9.50), greater than 89bio, Inc. (13.92), greater than Pliant Therapeutics, Inc. (14.47), greater than Arcellx, Inc. (6.01), greater than Stoke Therapeutics, Inc. (6.67), less than Viking Therapeutics, Inc. (37.69), greater than Intercept Pharmaceuticals, Inc. (4.22), greater than Terns Pharmaceuticals, Inc. (21.02), greater than Reata Pharmaceuticals, Inc. (3.21), greater than IVERIC bio, Inc. (15.53), greater than Blueprint Medicines Corporation (3.71), greater than Amylyx Pharmaceuticals, Inc. (4.66), greater than Karuna Therapeutics, Inc. (19.31), greater than Day One Biopharmaceuticals, Inc. (4.09),

Build a custom stock screener for Prometheus Biosciences, Inc. (RXDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prometheus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prometheus Biosciences, Inc. (RXDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prometheus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.